短放疗中断对口咽癌放化疗效果的影响
该研究纳入521例口咽鳞状细胞癌(OPSCC)连续队列患者,分析放疗中断(rTBs)和总治疗时间(OTT)延长对总生存(OS)、无病生存(DFS)、局部区域控制(LRC)及癌症复发的影响。结果显示,OTT延长≤2天或rTBs≤3天均未显著损害临床结局,连续中断≥3天亦无显著损害,但较长中断者竞争性死亡显著增加。
要点
- rTBs≤3天(连续或分散)与疾病失败无显著关联
- OTT延长≤2天未显著影响临床结局
- 较长中断者竞争性死亡显著增加,需进一步研究
核心结论
- 在根治性同步放化疗的OPSCC患者中,总rTBs≤3天(连续或分散)与疾病失败无显著关联。
- 较长中断者的竞争性死亡显著增加,需进一步研究更长中断的影响。
研究设计与样本
- 连续队列研究,纳入521例口咽鳞状细胞癌(OPSCC)患者。
- 采用竞争风险和多因素分析评估rTBs和OTT延长对OS、DFS、LRC及癌症复发的影响。
主要发现
- OTT延长≤2天或rTBs≤3天均未显著损害临床结局。
- 连续中断≥3天亦未显著损害临床结局。
- 较长中断者竞争性死亡显著增加。
临床怎么用
- 对于根治性同步放化疗的OPSCC患者,≤3天的放疗中断(连续或分散)可能不会显著影响疾病结局。
- 较长中断需警惕竞争性死亡风险增加,应个体化评估并进一步研究。
局限性
- 较长中断的影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous studies and guidelines suggest an outcome detriment from radiation treatment breaks (rTBs) and the need for compensatory dosing in patients with head and neck cancer. METHODS: In a consecutive cohort of 521 patients with oropharyngeal squamous cell carcinoma (OPSCC), we investigated the impact of rTBs and prolongation of overall treatment time (OTT) on OS, DFS, LRC, and cancer recurrence using competing risk and multivariate analyses. RESULTS: Neither OTT prolongation by ≤2 days nor rTBs of ≤3 days were associated with detriments to clinical outcomes. Consecutive breaks of ≥3 days were also not significantly associated with detriment to clinical outcomes. There was significantly increased competing mortality in those with longer breaks. CONCLUSIONS: In OPSCC patients treated with definitive concurrent chemoradiotherapy, there is no significant association between disease failure and total rTBs of ≤3 consecutive or scattered days. Further investigation is needed for longer breaks.
引用
- Rybkin A, Kang JJ, Lee A, et al. The effect of short radiation treatment breaks on chemo-radiotherapy for oropharyngeal cancers. Head Neck. 2021. PMID: 34585792. doi:10.1002/hed.26879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。